Evidence map›Paper›PMID 33991450›Full record

ArticlePhysiological reports2021

Antisense oligonucleotide-mediated knockdown of Mpzl3 attenuates the negative metabolic effects of diet-induced obesity in mice.

Beth L Worley, Thomas Auen, Amy C Arnold, Brett P Monia, Nadine Hempel, Traci A Czyzyk

Open access · goldAbstract read
In one paragraph

Article in Physiological reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Beth L WorleyDepartment of Anesthesiology & Perioperative Medicine, Penn State University College of Medicine, Hershey, PA, USA.
Thomas AuenDepartment of Anesthesiology & Perioperative Medicine, Penn State University College of Medicine, Hershey, PA, USA.
Amy C ArnoldDepartment of Neural & Behavioral Sciences, Penn State University College of Medicine, Hershey, PA, USA.
Brett P MoniaIonis Pharmaceuticals Inc., Carlsbad, CA, USA.
Nadine HempelDepartment of Pharmacology, Penn State University College of Medicine, Hershey, PA, USA.
Traci A CzyzykDepartment of Anesthesiology & Perioperative Medicine, Penn State University College of Medicine, Hershey, PA, USA.ORCID 0000-0002-3888-8338
Pennsylvania State University · USIonis Pharmaceuticals (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previously, we demonstrated that global knockout (KO) of the gene encoding myelin protein zero-like 3 (Mpzl3) results in reduced body weight and adiposity, increased energy expenditure, and reduced hepatic lipid synthesis in mice. These mice also exhibit cyclic and progressive alopecia which may contribute to the observed hypermetabolic phenotype. The goal of the current study was to determine if acute and peripherally restricted knockdown of Mpzl3 could ameliorate the negative metabolic effects of exposure to a high-fat and sucrose, energy-dense (HED) diet similar to what was observed in global Mpzl3 KO mice in the absence of a skin phenotype. Mpzl3 antisense oligonucleotide (ASO) administration dose-dependently decreased fat mass and circulating lipids in HED-fed C57BL/6N mice. These changes were accompanied by a decrease in respiratory exchange ratio, a reduction in energy expenditure and food intake, a decrease in expression of genes regulating de novo lipogenesis in white adipose tissue, and an upregulation of genes associated with steroid hormone biosynthesis in liver, thermogenesis in brown adipose tissue and fatty acid transport in skeletal muscle. These data demonstrate that resistance to the negative metabolic effects of HED is a direct effect of Mpzl3 knockdown, rather than compensatory changes that could be associated with deletion of Mpzl3 during development in global KO mice. Inhibiting MPZL3 could be a potential therapeutic approach for the treatment of obesity and associated dyslipidemia.

Indexed as

LipogenesisAdipose TissueAnimalsDiet, High-FatEnergy MetabolismGene Knockdown TechniquesMaleMembrane ProteinsMiceMice, Inbred C57BLMuscle, SkeletalObesityOligonucleotides, AntisenseMembrane ProteinsMpzl3 protein, mouseOligonucleotides, Antisensebeta-oxidationcholesteroldiet-induced obesityferredoxin reductaseinsulin resistancenon-alcoholic fatty liver disease

Identifiers

PMID33991450
PMCPMC8123547
OpenAlexW3162888918

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.